Treatment for Severe Coronavirus Disease 2019 with a biomimetic sorbent hemoperfusion device in patients on hemodialysis

Hemodialysis patients present more morbidity and mortality risk in coronavirus disease 2019. In patients who may develop severe symptoms the process called “viral sepsis” seems to be a crucial mechanism. In those cases, the hemodialysis procedure provides an excellent tool to explore the benefit of some extracorporeal therapies.

We reported the outcome of 4 hemodialysis patients with severe COVID-19 treated with Seraph100 hemoperfusion device. Three of four cases presented a good clinical response after hemoperfusion.

In conclusion, the treatment with Seraph100 device may be a simultaneous treatment to improve the hemodialysis patients with severe SARS-CoV-2.